475 related articles for article (PubMed ID: 9635530)
1. The extent of proliferative and apoptotic activity in intraductal and invasive ductal breast carcinomas detected by Ki-67 labeling and terminal deoxynucleotidyl transferase-mediated digoxigenin-11-dUTP nick end labeling.
Shen KL; Harn HJ; Ho LI; Yu CP; Chiu SC; Lee WH
Cancer; 1998 Jun; 82(12):2373-81. PubMed ID: 9635530
[TBL] [Abstract][Full Text] [Related]
2. Apoptosis occurs more frequently in intraductal carcinoma than in infiltrating duct carcinoma of human breast cancer and correlates with altered p53 expression: detected by terminal-deoxynucleotidyl-transferase-mediated dUTP-FITC nick end labelling (TUNEL).
Harn HJ; Shen KL; Yueh KC; Ho LI; Yu JC; Chiu SC; Lee WH
Histopathology; 1997 Dec; 31(6):534-9. PubMed ID: 9447384
[TBL] [Abstract][Full Text] [Related]
3. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
[TBL] [Abstract][Full Text] [Related]
4. p53 mutation in breast cancer. Correlation with cell kinetics and cell of origin.
Megha T; Ferrari F; Benvenuto A; Bellan C; Lalinga AV; Lazzi S; Bartolommei S; Cevenini G; Leoncini L; Tosi P
J Clin Pathol; 2002 Jun; 55(6):461-6. PubMed ID: 12037031
[TBL] [Abstract][Full Text] [Related]
5. Extensive apoptosis in ductal carcinoma in situ of the breast.
Bodis S; Siziopikou KP; Schnitt SJ; Harris JR; Fisher DE
Cancer; 1996 May; 77(9):1831-5. PubMed ID: 8646681
[TBL] [Abstract][Full Text] [Related]
6. Bax protein expression in DCIS of the breast in relation to invasive ductal carcinoma and other molecular markers.
Rehman S; Crow J; Revell PA
Pathol Oncol Res; 2000; 6(4):256-63. PubMed ID: 11173657
[TBL] [Abstract][Full Text] [Related]
7. Alterations of ER, PR, HER-2/neu, and P53 protein expression in ductal breast carcinomas and clinical implications.
Liu C; Zhang H; Shuang C; Lu Y; Jin F; Xu H; Lu P
Med Oncol; 2010 Sep; 27(3):747-52. PubMed ID: 19657752
[TBL] [Abstract][Full Text] [Related]
8. Breast density, scintimammographic (99m)Tc(V)DMSA uptake, and calcitonin gene related peptide (CGRP) expression in mixed invasive ductal associated with extensive in situ ductal carcinoma (IDC + DCIS) and pure invasive ductal carcinoma (IDC): correlation with estrogen receptor (ER) status, proliferation index Ki-67, and histological grade.
Papantoniou V; Sotiropoulou E; Valsamaki P; Tsaroucha A; Sotiropoulou M; Ptohis N; Stipsanelli A; Dimitrakakis K; Marinopoulos S; Tsiouris S; Antsaklis A
Breast Cancer; 2011 Oct; 18(4):286-91. PubMed ID: 20143189
[TBL] [Abstract][Full Text] [Related]
9. Spontaneous programmed cell death in infiltrating duct carcinoma: association with p53, BCL-2, hormone receptors and tumor proliferation.
Pillai MR; Kesari AL; Chellam VG; Madhavan J; Nair P; Nair MK
Pathol Res Pract; 1998; 194(8):549-57. PubMed ID: 9779489
[TBL] [Abstract][Full Text] [Related]
10. Identifying a highly-aggressive DCIS subgroup by studying intra-individual DCIS heterogeneity among invasive breast cancer patients.
Pape-Zambito D; Jiang Z; Wu H; Devarajan K; Slater CM; Cai KQ; Patchefsky A; Daly MB; Chen X
PLoS One; 2014; 9(6):e100488. PubMed ID: 24978026
[TBL] [Abstract][Full Text] [Related]
11. Breast carcinogenesis. Transition from hyperplasia to invasive lesions.
Meteoglu I; Dikicioglu E; Erkus M; Culhaci N; Kacar F; Ozkara E; Uyar M
Saudi Med J; 2005 Dec; 26(12):1889-96. PubMed ID: 16380768
[TBL] [Abstract][Full Text] [Related]
12. Microsatellite alterations on human chromosome 11 in in situ and invasive breast cancer: a microdissection microsatellite analysis and correlation with p53, ER (estrogen receptor), and PR (progesterone receptor) protein immunoreactivity.
Shen KL; Yang LS; Hsieh HF; Chen CJ; Yu JC; Tsai NM; Harn HJ
J Surg Oncol; 2000 Jun; 74(2):100-7. PubMed ID: 10914818
[TBL] [Abstract][Full Text] [Related]
13. Pleomorphic lobular carcinoma of the breast: its cell kinetics, expression of oncogenes and tumour suppressor genes compared with invasive ductal carcinomas and classical infiltrating lobular carcinomas.
Frolik D; Caduff R; Varga Z
Histopathology; 2001 Nov; 39(5):503-13. PubMed ID: 11737309
[TBL] [Abstract][Full Text] [Related]
14. Are the pure in situ breast ductal carcinomas and those associated with invasive carcinoma the same?
Schorr MC; Pedrini JL; Savaris RF; Zettler CG
Appl Immunohistochem Mol Morphol; 2010 Jan; 18(1):51-4. PubMed ID: 19568168
[TBL] [Abstract][Full Text] [Related]
15. Retinoic acid receptor and retinoid X receptor in ductal carcinoma in situ and intraductal proliferative lesions of the human breast.
Ariga N; Moriya T; Suzuki T; Kimura M; Ohuchi N; Sasano H
Jpn J Cancer Res; 2000 Nov; 91(11):1169-76. PubMed ID: 11092983
[TBL] [Abstract][Full Text] [Related]
16. Apoptosis in ductal carcinoma in situ of the breast.
Moreno A; Figueras A; Lloveras B; Escobedo A; Griera E; Sierra A; Fabra A
Breast J; 2001; 7(4):245-8. PubMed ID: 11678802
[TBL] [Abstract][Full Text] [Related]
17. Expression of Bcl-2, but not Bax, correlates with estrogen receptor status and tumor proliferation in invasive breast carcinoma.
Yang Q; Sakurai T; Jing X; Utsunomiya H; Shan L; Nakamura Y; Nakamura M; Oura S; Suzuma T; Yoshimura G; Umemura T; Kokawa Y; Kakudo K
Pathol Int; 1999 Sep; 49(9):775-80. PubMed ID: 10504548
[TBL] [Abstract][Full Text] [Related]
18. Bcl-2 expression and DNA fragmentation in breast carcinoma, pathologic and steroid hormone receptors correlates.
Diaz-Cano SJ; Garcia-Moliner M; Carney W; Wolfe HJ
Diagn Mol Pathol; 1997 Aug; 6(4):199-208. PubMed ID: 9360841
[TBL] [Abstract][Full Text] [Related]
19. Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trial.
Bundred NJ; Cramer A; Morris J; Renshaw L; Cheung KL; Flint P; Johnson R; Young O; Landberg G; Grassby S; Turner L; Baildam A; Barr L; Dixon JM
Clin Cancer Res; 2010 Mar; 16(5):1605-12. PubMed ID: 20179229
[TBL] [Abstract][Full Text] [Related]
20. Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer.
Wong H; Lau S; Yau T; Cheung P; Epstein RJ
Br J Cancer; 2010 Apr; 102(9):1391-6. PubMed ID: 20424617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]